Interpreting clinical assays for histone deacetylase inhibitors

Cancer Management and Research

Volumn 3, Issue 1, 2011, Pages 117-141

  Martinet, Nadine ^a   Bertrand, Philippe ^b  

^a UNIVERSITÉ DE NICE SOPHIA ANTIPOLIS   (France)

^b UNIVERSITÉ DE POITIERS   (France)

Author keywords

Clinical trials interpretation; Epigenetic; Histone deacetylase inhibitors

Indexed keywords

APICIDIN; AZACITIDINE; BELINOSTAT; BORTEZOMIB; CAPECITABINE; CISPLATIN; DACINOSTAT; DOCETAXEL; ENTINOSTAT; ETOPOSIDE; FLUOROURACIL; GIVINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; MOCETINOSTAT; NVPLAQ 824; PACLITAXEL; PANOBINOSTAT; PIVALOYLOXYMETHYL BUTYRATE; RAPAMYCIN; RESMINOSTAT; RETINOIC ACID; ROMIDEPSIN; SNX 275; SORAFENIB; TACEDINALINE; TAMOXIFEN; THIOTEPA; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; ANEMIA; ANOREXIA; APOPTOSIS; ASTHENIA; BLOOD TOXICITY; BRAIN DISEASE; BRAIN HEMORRHAGE; BRAIN TUMOR; BREAST CANCER; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CATALYSIS; CELL DIFFERENTIATION; CHROMATIN CONDENSATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CONFUSION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CUTANEOUS T CELL LYMPHOMA; DEACETYLATION; DEHYDRATION; DIARRHEA; DIZZINESS; DNA SEQUENCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; ENZYME INHIBITION; EPIGENETICS; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION PROFILING; GENE SILENCING; HALLUCINATION; HEARING LOSS; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; KIDNEY CARCINOMA; LEUKEMIA; LEUKEMIA RELAPSE; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHATIC LEUKEMIA; LYMPHOCYTOPENIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PERICARDIAL DISEASE; PLEIOTROPY; PLEURA MESOTHELIOMA; PNEUMONIA; POLYCYTHEMIA VERA; PROSTATE CANCER; PROTEIN LOCALIZATION; QT PROLONGATION; RESPIRATORY DISTRESS; REVIEW; SICK SINUS SYNDROME; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; SUDDEN DEATH; T WAVE INVERSION; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOSIS; THYROID CANCER; TUMOR; UPREGULATION; UTERINE CERVIX CANCER; VISUAL DISORDER; VOMITING;

EID: 79957839068     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMR.S9661     Document Type: Review

References (211)

1. Choudhuri S, Cui Y, Klaassen CD. Molecular targets of epigenetic regulation and effectors of environmental influences. Toxicol Appl Pharmacol. 2010;245(3):378-393
2. Santos-Rosa H, Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer. 2005;41(16):2381-2402
3. Oliver SS, Denu JM. Dynamic interplay between histone H3 modifications and protein interpreters: emerging evidence for a "histone language". Chembiochem. 2011;12(2):299-307
4. Zee BM, Levin RS, Dimaggio PA, et al. Global turnover of histone post-translational modifications and variants in human cells. Epigenetics Chromatin. 2010;3:22-33
5. Dekker F, Haisma HJ. Histone acetyl transferases as emerging drug targets. Drug Discovery Today. 2009;14(19/20):942-948
6. Lim S, Metzger E, Schüle R, et al. Epigenetic regulation of cancer growth by histone demethylases. Int J Cancer. 2010;127(9):1991-1998
7. Nicholson TB, Chen T, Richard S. The physiological and pathophysiological role of PRMT1-mediated protein arginine methylation. Pharmacol Res. 2009;60(6):466-474
8. Fackelmayer FO. Protein arginine methyltransferases: guardians of the Arg? Trends Biochem Sci. 2005;30(12):666-671
9. Tini M, Naeem H, Torchia J. Biochemical analysis of arginine methylation in transcription. Methods Mol Biol. 2009;523:235-247
10. Spannhoff AT, Hauser R, Heinke W, et al. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. ChemMedChem. 2009;4(10):1568-1582
11. Zhang Y, Xu K, Ni M, et al. Nucleosome dynamics define transcriptional enhancers. Nature Genetics. 2010;42(4):343-347
12. Copeland RA, Olhava EJ, Scott MP. Targeting epigenetic enzymes for drug discovery. Curr Opin Chem Biol. 2010;14(4):505-510
13. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415-428
14. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in purkinje neurons and the brain. Science. 2009;324(5929):929-930
15. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114(1):144-147
16. Fabbri M, Calin GA. Epigenetics and miRNAs in human cancer. Adv Genet. 2010;70:87-99
17. Zain J, Kaminetzki D, O'Connor OA. Emerging role of epigenetic therapies in cutaneous T-cell lymphomas. Expert Rev Hematol. 2010;3(2):187-203
18. Graham JS, Kaye SB, Brown R. The promises and pitfalls of epigenetic therapies in solid tumors. Eur J Cancer. 2009;45(7):1129-1136
19. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9): 5769-5784
20. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009;10(1):32-42
21. Razidlo DF, Whitney TJ, Casper ME, et al. Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PLoS One. 2010;5(7):e11492.
22. Bhaskara S, Chyla BJ, Amann JM, et al. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell. 2008;30(1):61-72
23. De Zoeten EF, Wang L, Sai H, et al. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology. 2010;138(2):583-594
24. Kotian S, Liyanarachchi S, Zelent A, et al. Histone deacetylases 9 and 10 are required for homologous recombination. J Biol Chem. Epub 2011 Jan 18.
25. Kelly G. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1. Altern Med Rev. 2010;15(3):245-263
26. Zhang Y, Kwon S, Yamaguchi T, et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol. 2008;28(5):1688-1701
27. Mai A, Altucci L. Epi-drugs to f ight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol. 2009;41(1):199-213
28. Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs. 2005;14(12):1497-1511
29. Bertrand P. Inside HDAC with HDAC inhibitors. Eur J Med Chem. 2010;45(6):2095-2116
30. Yurek-George A, Cecil AR, Mo AH, et al. The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor. J Med Chem. 2007;50(23):5720-5726
31. Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008;409(2):581-589
32. KrennHrubec K, Marshall BL, Hedglin M, et al. Design and evaluation of 'linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett. 2007;17(10):2874-2878
33. Estiu G, Greenberg E, Harrison CB, et al. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J Med Chem. 2008; 51(10):2898-2906
34. Taori K, Paul VJ, Luesch H. Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J Am Chem Soc. 2008;130(6):1806-1807
35. Huhtiniemi T, Suuronen T, Lahtela-Kakkonen M, et al. Nε-Modified lysine containing inhibitors for SIRT1 and SIRT2. Bioorg Med Chem. 2010;18(15):5616-5625
36. Huhtiniemi T, Wittekindt C, Laitinen T, et al. Comparative and pharmacophore model for deacetylase SIRT1. J Comput Aided Mol Des. 2006;20(9):589-599
37. Elaut G, Török G, Vinken M, et al. Major phase I biotransformation pathways of Trichostatin A in rat hepatocytes and in rat and human liver microsomes. Drug Metab Dispos. 2002;30(12):1320-1328
38. Ebbel EN, Leymarie N, Schiavo S, et al. Identification of phenylbutyrate- generated metabolites in Huntington disease patients using parallel liquid chromatography/electrochemical array/mass spectrometry and off-line tandem mass spectrometry. Analytical Biochem. 2010;399(2):152-161
39. Parise RA, Holleran JL, Beuner JH, et al. A liquid chromatography- electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum. J Chrom B. 2006;840(2):108-115
40. Du L, Musson DG, Wang AQ. Stability studies of vorinostat and its two metabolites in human plasma, serum and urine. J Pharm Biomed Anal. 2006;42(5):556-564
41. Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002;62(17):4916-4921
42. Xiao JJ, Byrd J, Marcucci G, et al. Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood. Rapid Commun Mass Spectrom. 2003;17(8):757-766
43. Shiraga T, Tozuka Z, Ishimura R, et al. Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull. 2005;28(1):124-129
44. Kim HM, Oh SJ, Park SK, et al. In vitro metabolism of KBH-A40, a novel delta-lactam-based histone deacetylase (HDAC) inhibitor, in human liver microsomes and serum. Xenobiotica. 2008;38(3):281-293
45. Fonsi M, Fiore F, Jones P, et al. Metabolism-related liabilities of a potent histone deacetylase (HDAC) inhibitor and relevance of the route of administration on its metabolic fate. Xenobiotica. 2009;39(10): 722-737
46. Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. PNAS. 2005;102(10):3697-3702
47. Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res. 2008;14(14):4500-4510
48. Kato N, Tanaka J, Sugita J, et al. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia. 2007;21(10):2103-2108
49. Vo DD, Prins RM, Begley JL, et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 2009;69(22):8693-8699
50. Cameron EE, Bachman KE, Myöhänen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21(1):103-107
51. Appelbaum FR, Baer MR, Carabasi MH, et al. NCCN Practice guidelines for acute myelogenous leukemia. Oncology. 2000;14(11A):53-61
52. Snykers S, Vinken M, Rogiers V, et al. Differential role of epigenetic modulators in malignant and normal stem cells: a novel tool in preclinical in vitro toxicology and clinical therapy. Arch Toxicol. 2007;81(8): 533-544
53. Marks PA, Miller T, Richon VM. Histone deacetylases. Curr Opin Pharmacol. 2003;3(4):344-351
54. DiGiuseppe JA, Weng LJ, Yu KH, et al. Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia. 1999;13(8):1243-1253
55. Carducci MA, Nelson JB, Chan-Tack KM, et al. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res. 1996;2(2):379-387
56. Zhang X, Wei L, Yang Y, Yu Q. Sodium 4-phenylbutyrate induces apoptosis of human lung carcinoma cells through activating JNK pathway. J Cell Biochem. 2004;93(4):819-829
57. Gorospe M, Shack S, Guyton KZ, et al. Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate. Cell Growth Differ. 1996;7(12): 1609-1615
58. Liu L, Hudgins WR, Miller AC, et al. Transcriptional upregulation of TGF-α by phenylacetate and phenylbuytrate is associated with differentiation of human melanoma cells. Cytokine. 1995;7(5):449-456
59. Han S, Wada RK, Sidell N. Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferatoractivated receptor gamma. Cancer Res. 2001;61(10):3998-4002
60. Carducci MA, Nelson JB, Chan-Tack KM, et al. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res. 1996;2(2):379-387
61. Brusilow SW. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res. 1991;29(2):147-150
62. Phuphanich S, Baker SD, Grossman SA, et al. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol. 2005;7(2):177-182
63. Carducci MA, Gilbert J, Bowling MK, et al. A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res. 2001;7(10):3047-3055
64. Gilbert J, Baker SD, Bowling MK, et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res. 2001;7(8): 2292-2300
65. Camacho LH, Olson J, Tong WP, et al. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs. 2007;25(2):131-138
66. Gore SD, Weng LJ, Zhai S, et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res. 2002;8(4): 963-970
67. Maslak P, Chanel S, Camacho LH, et al. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia. 2006;20(2):212-217
68. Gilbert J, Baker SD, Donehower R, et al. Methytransferase (MT) activity and gene expression in tumor biopsies from patients enrolled in a Phase I study of the MT inhibitor, 5-azacytidine (5AC), and the histone deacetylase inhibitor, phenylbutyrate (PB), in refractory solid tumors. Proc Am Soc Clin Onc. 2001:87a.
69. Sung MW, Waxman S. Combination of cytotoxicdifferentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. Anticancer Res. 2007;27(2):995-1001
70. Rephaeli A, Rabizadeh E, Aviram A, et al. Derivatives of butyric acid as potential anti-neoplastic agents. Int J Cancer. 1991;49(1):66-72
71. Schwartz B, Avivi-Green C, Polak-Charcon S. Sodium butyrate induces retinoblastoma protein dephosphorylation, p16 expression and growth arrest of colon cancer cells. Mol Cell Biochem. 1998;188(1-2): 21-30
72. Mandal M, Adam L, Kumar R. Redistribution of activated caspase-3 to the nucleus during butyric acid-induced apoptosis. Biochem Biophys Res Commun. 1999;260(3):775-780
73. Rabizadeh E, Shaklai M, Nudelman A, et al. Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug. FEBS Lett. 1993;328(3):225-229
74. Rabizadeh E, O. Bairey, Aviram A, et al. Doxorubicin and a butyric acid derivative effectively reduce levels of Bcl-2 protein in the cells of chronic lymphocytic leukemia patient. Eur J Haematol. 2001;66(4): 263-271
75. Patnaik A, Rowinsky EK, Villalona MA, et al. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin Cancer Res. 2002;8(7):2142-2148
76. Reid T, Valone F, Lipera W, et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer. 2004;45(3): 381-386
77. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002;16(10): 669-694
78. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16(10): 695-714
79. Marchion DC, Bicaku E, Daud AI, et al. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res. 2005;65(9):3815-3822
80. Jung GA, Yoon JY, Moon BS, et al. Valproic acid induces differentiation and inhibition of proliferation in neural progenitor cells via the beta-catenin-Ras-ERK-p21Cip/WAF1 pathway. BMC Cell Biol. 2008; 9:66-78
81. Gottlicher M, Minucci S, Zhu J, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20(24):6969-6978
82. Gurvich N, Tsygankova OM, Meinkoth JL, et al. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res. 2004;64(3):1079-1086
83. Bacon CL, Gallagher HC, Haughey JC, et al. Antiproliferative action of valproate is associated with aberrant expression and nuclear translocation of cyclin D3 during the C6 glioma G1 phase. J Neurochem. 2002;83(1):12-19
84. Werling U, Siehler S, Litfin M, et al. Induction of differentiation in F9 cells and activation of peroxisome proliferator-activated receptor delta by valproic acid and its teratogenic derivatives. Mol Pharmacol. 2001;59(5):1269-1276
85. Kawagoe R, Kawagoe H, Sano K. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase dependent and -independent apoptotic signaling pathways. Leuk Res. 2002;26(5):495-502
86. Tang R, Faussat AM, Majdak P, et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia. 2004;18(7):1246-1251
87. Ichiyama T, Okada K, Lipton JM, et al. Sodium valproate inhibits production of TNF-α and IL-6 and activation of NF-κB. Brain Res. 2000;857(1-2):246-251
88. Siitonen T, Koistinen P, Savolainen ER. Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells. Leuk Res. 2005;29(11):1335-1342
89. Cimino G, Lo-Coco F, Fenu S, et al. Sequential valproic acid/Alltrans retinoic acid treatment reprograms differentiation in refractory and highrisk acute myeloid leukemia. Cancer Res. 2006;66(17):8903-8911
90. Valentini A, Gravina P, Federici G, et al. Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol Ther. 2007;6(2):185-191
91. Atmaca A, Al-Batran SE, Maurer A, et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating Phase I clinical trial. British J Cancer. 2007;97(2):177-182
92. Bug G, Ritter M, Wassmann B, et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer. 2005;104(12):2717-2725
93. Kuendgen A, Knipp S, Fox F, et al. Results of a Phase 2 study of valproic acid alone or in combination with alltrans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol. 2005;84(Suppl 1): 61-66
94. Pilatrino C, Cilloni D, Messa E, et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer. 2005;104(1):101-109
95. Raffoux E, Chaibi P, Dombret H, et al. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica. 2005;90(7):986-988
96. Duprez E, Lillehaug JR, Naoe T, et al. cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha. Oncogene. 1996;12(11):2451-2459
97. Kuendgen A, Schmid M, Schlenk R, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer. 2006;106(1):112-119
98. Huang S, Brandt SJ. mSin3A regulates murine erythroleukemia cell differentiation through association with the TAL1 (or SCL) transcription factor. Mol Cell Biol. 2000;20(6):2248-2259
99. Watamoto K, Towatari M, Ozawa Y, et al. Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation. Oncogene. 2003;22(57):9176-9184
100. Siitonen T, Timonen T, Juvonen E, et al. Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. Haematologica. 2007;92(8):1119-1122
101. Santini V, Ferrini PR. Differentiation therapy of myelodysplastic syndromes: fact or fiction? Br J Heamatol. 1998;102(5):1124-1138
102. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108(10):3271-3279
103. Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007;25(25):3884-3891
104. Braiteh F, Soriano AO, Garcia-Manero G, et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res. 2008;14(19): 6296-6301
105. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110(7):2302-2308
106. Münster P, Marchion D, Bicaku E, et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: Phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res. 2009;15(7):2488-2496
107. Münster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncology. 2007;25(15):1979-1985
108. Daud AI, Dawson J, DeConti RC, et al. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and Phase I/II clinical trial. Clin Cancer Res. 2009;15(7):2479-2489
109. Rocca A, Minucci S, Tosti G, et al. A Phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. British J Cancer. 2009;100(1):28-36
110. Fachetti F, Previdi S, Ballarini M, et al. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis. 2004;9(5):573-582
111. Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A Phase I study. Mol Cancer. 2005;4(1):22.
112. Candelaria M, Gallardo-Rincon D, Arce C, et al. A Phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol. 2007;18(9):1529-1538
113. Parulekar WR, Einsenhauer EA. Novel endpoints and design of early clinical trials. Annal Oncol. 2002;13(Suppl 4):139-143
114. Hunsberger S, Rubinstein LV, Dancey J, et al. Dose escalation trial designs based on a molecularly targeted endpoint. Stat Med. 2005;24(14):2171-2181
115. Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, et al. Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine. J Transl Med. 2006;4:32.
116. Richon VM, Webb Y, Merger R, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A. 1996;93(12):5705-5708
117. Butler LM, Agus DB, Scher HL, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000;60(78): 5165-5170
118. Finnin MS, Donigian JR, Cohen A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999;401(6749):188-193
119. Yin D, Ong JM, Hu J, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res. 2007;13(3):1045-1052
120. Mitsiades CS, Poulaki V, McMullan C, et al. Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res. 2005;11(10):3958-3965
121. Munster PN, Troso-Sandoval T, Rosen N, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 2001;61(23): 8492-8497
122. Bali P, Pranpat M, Swaby R, et al. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin Cancer Res. 2005;11(17):6382-6389
123. Komatsu N, Kawamata N, Takeuchi S, et al. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep. 2006;15(1):187-191
124. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000;60(18); 5165-5170
125. Dietrich C, Greenberg VL, Desimone CP, et al. Suberoylanilide hydroxamic acid potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines. Gynecol Oncol. 2006;116(1):126-130
126. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003;9:(10 Pt 1): 3578-3588
127. Krug LM, Curley T, Schwartz L, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer. 2006;7(4):257-261
128. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23(17):3923-3931
129. Garcia-Manero G, Yangn H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias andmyelodysplastic syndromes. Blood. 2008;111(3):1060-1066
130. Modesitt SC, Sill M, Hoffman JS, et al. A Phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;109(2):182-186
131. Vansteenkiste J, Van Cutsem E, Dumez H, et al. Early Phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or nonsmall cell lung cancer. Invest New Drugs. 2008;26(5):483-488
132. Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs. 2008;26(1):81-87
133. Luu TH, Morgan RJ, Leong L, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res. 2008;14(21):7138-7142
134. Galanis E, Jaeckle KA, Maurer MJ, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol. 2009;27(12):2052-2058
135. Woyach JA, Kloos RT, Ringel MD, et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab. 2009;94(1):164-170
136. Ramalingam SS, Parise RA, Ramanathan RK, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res. 2007;13(12):3605-3610
137. Plumb JA, Finn PW, Williams RJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2003;2(8):721-728
138. Gimsing P. Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor. Expert Opin Investig Drugs. 2009;18(4):501-508
139. Gian X, LaRochelle WJ, Ara G, et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther. 2006;5(8):2086-2095
140. Monks A, Hose CD, Pezzoli P, et al. Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. Anticancer Drugs. 2009;20(8):682-692
141. Warren KE, McCully C, Dvinge H, et al. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates. Cancer Chemother Pharmacol. 2008;62(3):433-437
142. Tumber A, Collins LS, Petersen K, et al. The histone deacetylase inhibitor PXD101 synergises with 5-Xuorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol. 2007;60:275-283
143. Steele NL, Plumb JA, Vidal L, et al. A Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 2008;14(3):804-810
144. Takada M, Kataoka A, Toi M, et al. A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. Int J Oncol. 2004;25(2): 397-405
145. Gimsing P, Hansen M, Knudsen LM, et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Hematol. 2008;81(3):170-176
146. Ramalingam SS, Belani CP, Ruel C, et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 2009;4(1):97-101
147. Mackay HJ, Hirte H, Colgan T, et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer. 2010;46(9):1573-1579
148. Golay J, Cuppini L, Leoni F, et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia. 2007;21(9):1892-1900
149. Viviani S, Bonfante V, Fasola C, et al. Phase II study of the histonedeacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin's lymphoma patients. J Clin Oncol. 2008;26:abstract 8532.
150. Galli M, Salmoiraghi S, Golay J, et al. A Phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol. 2010;89(2):185-190
151. Carlo-Stella C, Guidetti A, Viviani S, et al. Safety and clinical activity of the histone deacetylase inhibitor givinostat in combination with meclorethamine in relapsed/refractory Hodgkin lymphoma (HL). J Clin Oncol. 2010;28:abstract 3068.
152. Qian DZ, Kato Y, Shabbeer S, et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res. 2006;12(2):634-642
153. Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol. 2009;5(5):601-612
154. Giles F, Fischer T, Cortes J, et al. Phase I Study of Intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006;12(15):4628-4635
155. Rathkopf D, Wong BY, Ross RW, et al. A Phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2010;66(1):181-189
156. Remiszewski SW. The discovery of NVPLAQ824: from concept to clinic. Curr Med Chem. 2003;10(22):2393-2402
157. Hurtubise A, Momparler RL. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother Pharmacol. 2006;58(5):618-625
158. De Bono JS, Kristeleit R, Tolcher A, et al. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res. 2008;14(20):6663-6673
159. Kristeleit RS, Tandy D, Atadja P, et al. Effects of the histone deacetylase inhibitor (HDACI) LAQ824 on histone acetylation, Hsp70 and c-Raf in peripheral blood lymphocytes from patients with advanced solid tumours enrolled in a phase I clinical trial. J Clin Oncol. 2004;22:abstract 3023.
160. Ottmann OG, Deangelo DJ, Stone RM, et al. A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies. J Clin Oncol. 2004;22:abstract 3024.
161. Choy E, Cao Y, Hornicek F, et al. Effect of histone deacetylase inhibitor (HDACI) PCI-24781 on chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines. J Clin Oncol. 2010;28:abstract 10089.
162. Undevia SD, Janisch L, Schilsky RL, et al. Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781. J Clin Oncol. 2008;26:abstract 14514.
163. Jaboin J, Wild J, Hamidi H, et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 2002;62(21):6108-6115
164. Lucas DM, Davis ME, Parthun MR, et al. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia. 2004;18(7):1207-1214
165. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 2003;63(13): 3637-3645
166. Lee BI, Park SH, Kim JW, et al. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. Cancer Res. 2001;61(3): 931-934
167. Acharya MR, Sparreboom A, Sausville EA, et al. Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. Cancer Chemother Pharmacol. 2006;57(3):275-281
168. Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol. 2005;23(17):3912-3922
169. Kummar S, Gutierrez M, Gardner ER, et al. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res. 2007; 13(18 Pt 1):5411-5417
170. Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 2007;109(7):2781-2790
171. Gore L, Rothenberg ML, O'Bryant CL, et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res. 2008;14(14):4517-4525
172. Hauschild A, Trefzer U, Garbe C, et al. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)- carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res. 2008;18(4):274-278
173. Zhou N, Moradei O, Raeppel S, et al. Discovery of N-(2- aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacethylase inhibitor. J Med Chem. 2008;51(14):4072-4075
174. Fournel M, Bonfils C, Hou Y, et al. MGCD0103, a novel isotypeselective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther. 2008;7(4):759-768
175. Siu LL, Pili R, Duran I, et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol. 2008;26(12):1940-1947
176. Garcia-Manero G, Assouline S, Cortes J, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008;112(4):981-989
177. Lancet JE, Nichols G, Assouline S, et al. A Phase I study of MGCD0103 given as a twice weekly oral dose in patients with advanced leukemias or myelodysplastic syndromes (MDS). J Clin Oncol. 2007;25:abstract 2516.
178. Bociek RG, Kuruvilla GJ, Pro B, et al. Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL). J Clin Oncol. 2008;26:abstract 8507.
179. Martell RE, Younes A, Assouline SE, et al. Phase II study of MGCD0103 in patients with relapsed follicular lymphoma (FL): Study reinitiation and update of clinical efficacy and safety. J Clin Oncol. 2010;28:abstract 8086.
180. Berger MR, Bischoff H, Fritschi E, et al. Synthesis, toxicity, and therapeutic efficacy of 4-amino-N-(2-aminophenyl) benzamide: a new compound preferentially active in slowly growing tumors. Cancer Treat Rep. 1985;69(12):1415-1424
181. Kraker AJ, Mizzen CA, Hartl BG, et al. Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. Mol Cancer Ther. 2003;2(4):401-408
182. Prakash S, Foster BJ, Meyer M, et al. Chronic oral administration of CI-994: a Phase 1 study. Invest New Drugs. 2001;19(1):1-11
183. Undevia SD, Kindler HL, Janisch L, et al. A Phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004;15(11):1705-1711
184. Richards DA, Boehm KA, Waterhouse DM, et al. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol. 2006;17(7):1096-1102
185. Ueda H, Manda T, Matsumoto S, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968, III: antitumor activities on experimental tumors in mice. J Antibiot. 1994;47(3):315-323
186. Ueda H, Nakajima H, Hori Y, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physicochemical and biological properties, and antitumor activity. J Antibiot. 1994;47(3):301-310
187. Yu XD, Wang SY, Chen GA, et al. Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells. Cancer J. 2007;13(2):105-113
188. Sandor V, Robbins AR, Robey R, et al. FR901228 causes mitotic arrest but does not alter microtubule polymerization. Anticancer Drugs. 2000;11(11):445-454
189. Sandor V, Senderowicz A, Mertins S, et al. P21-dependent G(1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer. 2000;83(6):817-825
190. Wang R, Brunner T, Zhang L, et al. Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression. Oncogene. 1998;17(12):1503-1508
191. Yu X, Guo ZS, Marcu MG, et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst. 2002;94(7):504-513
192. Rajgolikar G, Chan KK, Wang HC. Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast Cancer Res Treat. 1998;51(1):29-38
193. Kitazono M, Robey R, Zhan Z, et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na/I symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab. 2001;86(7):3430-3435
194. Aron JL, Parthun MR, Marcucci G, et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood. 2003;102(2):652-658
195. Weiser TS, Guo ZS, Ohnmacht GA, et al. Sequential 5-aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother. 2001;24(2):151-161
196. Steiner FA, Hong JA, Fischette MR, et al. Sequential 5-Aza 2-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene. 2005;24(14):2386-2397
197. Klisovic MI, Maghraby EA, Parthun MR, et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ ETO-positive leukemic cells. Leukemia. 2003;17(2):350-358
198. Sasakawa Y, Naoe Y, Sogo N, et al. Marker genes to predict sensitivityto FK228, a histone deacetylase inhibitor. Biochem Pharmacol. 2005;69(4):603-616
199. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410-5417
200. Woo S, Gardner ER, Chen X, et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009;15(4):1496-1503
201. Marshall JL, Rizvi N, Kauh J, et al. A Phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol. 2002;2(6):325-332
202. Sandor V, Bakkes S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002;8(3);718-728
203. Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005;105(3):959-967
204. Fouladi M, Furman WL, Chin T, et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J Clin Oncol. 2006;24(22):3678-3685
205. Klimek VM, Fircanis S, Maslak P, et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res. 2008;14(3):826-832
206. Stadler WM, Margolin K, Ferber S, et al. A Phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006;5(1):57-60
207. Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2006;12(13):3997-4003
208. Schrump DS, Fischette MR, Nguyen DM, et al. Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res. 2008;14(1):188-198
209. Sosman JA, Aronson FR, Sznol M, et al. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible doselimiting neurological toxicity. Clin Cancer Res. 1997;3(1):39-46
210. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther. 2002;2(1):3-24
211. Bantscheff M, Hopf C, Savitski MM, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol. 2011. In press.